On Jan. 21, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The Phase 3 BLAZE-2 COVID-19 prevention trial ﾖ conducted in partnership with the NIAID, and the COVID-19 Prevention Network ﾖ enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.